Information de reference pour ce titreAccession Number: | 00000605-201311190-00007.
|
Author: | Richardson, Karl MD *; Schoen, Marisa BA *; French, Benjamin PhD; Umscheid, Craig A. MD, MSCE; Mitchell, Matthew D. PhD; Arnold, Steven E. MD; Heidenreich, Paul A. MD, MS; Rader, Daniel J. MD; deGoma, Emil M. MD
|
Institution: | From the Perelman School of Medicine, University of Pennsylvania, and University of Pennsylvania Health System, Philadelphia, Pennsylvania, and Stanford University Medical Center, Stanford, California.
|
Title: | |
Source: | Annals of Internal Medicine. 159(10):688-697, November 19, 2013.
|
Abstract: | Background: Despite the U.S. Food and Drug Administration (FDA) warning regarding cognitive impairment, the relationship between statins and cognition remains unknown.
Purpose: To examine the effect of statins on cognition.
Data Sources: PubMed, Embase, and Cochrane Library from inception through October 2012; FDA databases from January 1986 through March 2012.
Study Selection: Randomized, controlled trials (RCTs) and cohort, case-control, and cross-sectional studies evaluating cognition in patients receiving statins.
Data Extraction: Two reviewers extracted data, 1 reviewer assessed study risk of bias, and 1 reviewer checked all assessments.
Data Synthesis: Among statin users, low-quality evidence suggested no increased incidence of Alzheimer disease and no difference in cognitive performance related to procedural memory, attention, or motor speed. Moderate-quality evidence suggested no increased incidence of dementia or mild cognitive impairment or any change in cognitive performance related to global cognitive performance scores, executive function, declarative memory, processing speed, or visuoperception. Examination of the FDA postmarketing surveillance databases revealed a low reporting rate for cognitive-related adverse events with statins that was similar to the rates seen with other commonly prescribed cardiovascular medications.
Limitations: The absence of many well-powered RCTs for most outcomes resulted in final strengths of evidence that were low or moderate. Imprecision, inconsistency, and risk of bias also limited the strength of findings.
Conclusion: Larger and better-designed studies are needed to draw unequivocal conclusions about the effect of statins on cognition. Published data do not suggest an adverse effect of statins on cognition; however, the strength of available evidence is limited, particularly with regard to high-dose statins.
Primary Funding Source: None.
(C) 2013 American College of Physicians
|
References: | 1.Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366:1752-5. [PMID: 22533536]
2.Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. [PMID: 16214597]
3.Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14. [PMID: 16453090]
4.Anderson S. Upbeat boomers say they're not old yet. USA Today. 14 July 2011. Accessed at http://usatoday30.usatoday.com/n...- ouverture dans une nouvelle fenêtre on 2 October 2013.
5.Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217]
6.Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2010. Accessed at www.ohri.ca/programs/clinical_epidemiology/oxford.asp in April 2013.
7.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
8.Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software. 2010;36:1-48.
9.Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94. [PMID: 21195583]
10.Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ; GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-8. [PMID: 18456631]
11.Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. [PMID: 18436948]
12.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. [PMID: 12114036]
13.Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al; Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-24. [PMID: 15699299]
14.Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20. [PMID: 17640385]
15.Szwast SJ, Hendrie HC, Lane KA, Gao S, Taylor SE, Unverzagt F, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology. 2007;69:1873-80. [PMID: 17984456]
16.Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67:99-109. [PMID: 19006546]
17.Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62:1047-51. [PMID: 16009757]
18.Parikh NM, Morgan RO, Kunik ME, Chen H, Aparasu RR, Yadav RK, et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011;26:749-57. [PMID: 20891020]
19.Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197. [PMID: 20488911]
20.Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011;65:949-57. [PMID: 20841372]
21.Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis. 2012;21:436-44. [PMID: 21236699]
22.Ancelin ML, Carriere I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis. 2012;30:629-37. [PMID: 22451317]
23.Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-31. [PMID: 11089820]
24.Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-7. [PMID: 11843693]
25.Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50:1852-6. [PMID: 12410906]
26.Horsdal HT, Olesen AV, Gasse C, Sorensen HT, Green RC, Johnsen SP. Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Assoc Disord. 2009;23:18-22. [PMID: 18695588]
27.Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5:416-21. [PMID: 18690839]
28.Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58:1311-7. [PMID: 20533968]
29.Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13-7. [PMID: 18931004]
30.Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-802. [PMID: 18199831]
31.Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA; MIRAGE Study Group. Statin use and the risk of Alzheimer's disease: the MIRAGE study. Alzheimers Dement. 2006;2:96-103. [PMID: 19595865]
32. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology. 2004;23:94-8. [PMID: 14739574]
33. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-43. [PMID: 11030795]
34. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-84. [PMID: 11890840]
35. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344-50. [PMID: 18663180]
36. Rockwood K, Howlett S, Fisk J, Darvesh S, Tuokko H, Hogan DB, et al. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology. 2007;29:201-7. [PMID: 18043005]
37. Carlsson CM, Nondahl DM, Klein BE, McBride PE, Sager MA, Schubert CR, et al. Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord. 2009;23:11-7. [PMID: 19266697]
38. Glasser SP, Wadley V, Judd S, Kana B, Prince V, Jenny N, et al. The association of statin use and statin type and cognitive performance: analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Clin Cardiol. 2010;33:280-8. [PMID: 20513066]
39. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. [PMID: 12457784]
40. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, et al; Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65:1388-94. [PMID: 16275825]
41. Starr JM, McGurn B, Whiteman M, Pattie A, Whalley LJ, Deary IJ. Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry. 2004;19:327-32. [PMID: 15065225]
42. Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, van der Grond J, et al; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia. 2007;50:2388-97. [PMID: 17764005]
43. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21:95-102. [PMID: 20413854]
44. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956-64. [PMID: 20200346]
45. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556-63. [PMID: 21795660]
46. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-50. [PMID: 12205648]
47. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753-7. [PMID: 15883262]
48. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-97. [PMID: 18316756]
49. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73:674-80. [PMID: 19720973]
50. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:1624-9. [PMID: 16291883]
51. Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis. 2010;7:183-6. [PMID: 20224282]
52. Winblad B, Jelic V, Kershaw P, Amatniek J. Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging. 2007;24:57-61. [PMID: 17233547]
53. Ellul J, Archer N, Foy CM, Poppe M, Boothby H, Nicholas H, et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2007;78:233-9. [PMID: 17012333]
54. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57:M414-8. [PMID: 12084801]
55. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:883-92. [PMID: 18978249]
56. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008;13:187-97. [PMID: 18376061]
57. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72:805-12. [PMID: 11565814]
58. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-96. [PMID: 7836550]
59. Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-46. [PMID: 10806282]
60. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823-9. [PMID: 15589485]
61. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27:183-90. [PMID: 17253908]
62. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning [Letter]. Diabetes Care. 2002;25:1250-1. [PMID: 12087035]
63. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39:333-6. [PMID: 7619678]
64. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209-14. [PMID: 7788948]
65. Prajapati S, Desai CK, Dikshit RK. An evaluation of the effect of atorvastatin on memory and psychomotor functions in hypertensive patients. J Postgrad Med. 2011;57:291-7. [PMID: 22120857]
66. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426-32. [PMID: 1617822]
67. Carlsson CM, Papcke-Benson K, Carnes M, McBride PE, Stein JH. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging. 2002;19:793-805. [PMID: 12390056]
68. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231-6. [PMID: 8198930]
69. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45:8-14. [PMID: 8994481]
70. Scudder LS, Egan AG. Statins: The story behind the label changes. Medscape. 6 March 2012. Accessed at www.medscape.com/viewarticle/759736 on 2 October 2013.
71. Ali S, Khan SA, Iram S. Hypocholesterolemia secondary to atrovastatin therapy. J Ayub Med Coll Abbottabad. 2010;22:225-7. [PMID: 22338462]
72. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800-11. [PMID: 19558254]
73. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190-2. [PMID: 16863497]
74. Healy D, Morgan R, Chinnaswamy S. Transient global amnesia associated with statin intake. BMJ Case Rep. 2009;2009. [PMID: 21686951]
75. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23:1663-7. [PMID: 14695047]
76. Okeahialam BN, Isiguzoro I. Statin related memory dysfunction in a Nigerian woman: a case report. Curr Drug Saf. 2012;7:33-4. [PMID: 22663955]
77. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-9. [PMID: 11401190]
78. Parker BA, Polk DM, Rabdiya V, Meda SA, Anderson A, Hawkins KA, et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy. 2010;30:625.
79. Parker BA, Polk DM, Rabdiya V, Meda SA, Anderson A, Hawkins KA, Pearlson GD, et al. The effect of various topical antibiotic and antibacterial agents on the middle and inner ear of the guinea-pig. Pharmacotherapy. 2010;30:625. [PMID: 24712]
80. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30:195-201. [PMID: 17343428]
81. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-80. [PMID: 12885101]
82. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60:875-81. [PMID: 22902202]
83. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011;64:1283-93. [PMID: 21839614]
84. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol. 2011;64:1294-302. [PMID: 21803546]
85. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-15. [PMID: 21247734]
86. Strom BL. How the US drug safety system should be changed. JAMA. 2006;295:2072-5. [PMID: 16670415]
|
Language: | English.
|
Document Type: | Review.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0003-4819
|
NLM Journal Code: | 0372351, 5a6
|
Annotation(s) | |
|
|